Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.

Published on Sep 1, 2020in JAMA Neurology18.302
· DOI :10.1001/JAMANEUROL.2020.2581
Céline Louapre19
Estimated H-index: 19
(French Institute of Health and Medical Research),
Nicolas Collongues31
Estimated H-index: 31
(French Institute of Health and Medical Research)
+ 17 AuthorsCovisep investigators1
Estimated H-index: 1
Importance Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities. Objective To describe the clinical characteristics and outcomes in patients with MS and COVID-19 and identify factors associated with COVID-19 severity. Design, Setting, and Participants The Covisep registry is a multicenter, retrospective, observational cohort study conducted in MS expert centers and general hospitals and with neurologists collaborating with MS expert centers and members of the Societe Francophone de la Sclerose en Plaques. The study included patients with MS presenting with a confirmed or highly suspected diagnosis of COVID-19 between March 1, 2020, and May 21, 2020. Exposures COVID-19 diagnosed with a polymerase chain reaction test on a nasopharyngeal swab, thoracic computed tomography, or typical symptoms. Main Outcomes and Measures The main outcome was COVID-19 severity assessed on a 7-point ordinal scale (ranging from 1 [not hospitalized with no limitations on activities] to 7 [death]) with a cutoff at 3 (hospitalized and not requiring supplemental oxygen). We collected demographics, neurological history, Expanded Disability Severity Scale score (EDSS; ranging from 0 to 10, with cutoffs at 3 and 6), comorbidities, COVID-19 characteristics, and outcomes. Univariate and multivariate logistic regression models were used to estimate the association of collected variables with COVID-19 outcomes. Results A total of 347 patients (mean [SD] age, 44.6 [12.8] years, 249 women; mean [SD] disease duration, 13.5 [10.0] years) were analyzed. Seventy-three patients (21.0%) had a COVID-19 severity score of 3 or more, and 12 patients (3.5%) died of COVID-19. The median EDSS was 2.0 (range, 0-9.5), and 284 patients (81.8%) were receiving DMT. There was a higher proportion of patients with a COVID-19 severity score of 3 or more among patients with no DMT relative to patients receiving DMTs (46.0% vs 15.5%;P  Conclusions and Relevance In this registry-based cohort study of patients with MS, age, EDSS, and obesity were independent risk factors for severe COVID-19; there was no association found between DMTs exposure and COVID-19 severity. The identification of these risk factors should provide the rationale for an individual strategy regarding clinical management of patients with MS during the COVID-19 pandemic.
Figures & Tables
📖 Papers frequently viewed together
#1Kenneth I. Zheng (WMU: Wenzhou Medical College)H-Index: 20
#2Feng Gao (WMU: Wenzhou Medical College)H-Index: 6
Last. Ming-Hua Zheng (WMU: Wenzhou Medical College)H-Index: 48
view all 11 authors...
Background & Aims. Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. Patients with metabolic associated fatty liver disease (MAFLD) are often obese and have additional metabolic risk factors which may aggravate the severity of respiratory diseases and of COVID-19. This study aims to investigate the association between MAFLD and COVID-19 severity. Methods 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75 years from three hospitals in Wenzhou, China wer...
BACKGROUND: Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks of disease complications due to dampened immune response. However, it has been speculated that overactive immune response could drive clinical deterioration and, based on this hy...
#1Carol H. Yan (UCSD: University of California, San Diego)H-Index: 15
#2Farhoud Faraji (UCSD: University of California, San Diego)H-Index: 20
Last. Adam S. DeConde (UCSD: University of California, San Diego)H-Index: 24
view all 5 authors...
BACKGROUND: Rapid spread of the SARS-CoV-2 virus has left many health systems around the world overwhelmed, forcing triaging of scarce medical resources. Identifying indicators of hospital admission for Covid-19 patients early in the disease course could aid the efficient allocation of medical interventions. Self-reported olfactory impairment has recently been recognized as a hallmark of Covid-19 and may be an important predictor of clinical outcome. METHODS: A retrospective review of all patien...
#4Joep Killestein (OHSU: Oregon Health & Science University)H-Index: 1
#5O Ciccarelli (OHSU: Oregon Health & Science University)H-Index: 15
The emergence of novel Coronavirus 2019 (COVID-19)1 and the subsequent pandemic present a unique challenge to Neurologists managing patients with multiple sclerosis (MS) and related neuroinflammatory disorders, such as neuromyelitis spectrum disorder (NMOSD).
#1Céline Louapre (University of Paris)H-Index: 19
#2Elisabeth Maillart (University of Paris)H-Index: 17
Last. C. Papeix (University of Paris)H-Index: 8
view all 7 authors...
#1Robert Verity (ICL: Imperial College London)H-Index: 31
#2Lucy C Okell (ICL: Imperial College London)H-Index: 51
Last. Neil M. Ferguson (ICL: Imperial College London)H-Index: 104
view all 33 authors...
Summary Background In the face of rapidly changing data, a range of case fatality ratio estimates for coronavirus disease 2019 (COVID-19) have been produced that differ substantially in magnitude. We aimed to provide robust estimates, accounting for censoring and ascertainment biases. Methods We collected individual-case data for patients who died from COVID-19 in Hubei, mainland China (reported by national and provincial health commissions to Feb 8, 2020), and for cases outside of mainland Chin...
#1Safiya Richardson (Hofstra University)H-Index: 10
#2Jamie S. Hirsch (Hofstra University)H-Index: 15
Last. Theodoros P. ZanosH-Index: 17
view all 27 authors...
Importance: There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19). Objective: To describe the clinical characteristics and outcomes of patients with COVID-19 hospitalized in a US health care system. Design, Setting, and Participants: Case series of patients with COVID-19 admitted to 12 hospitals in New York City, Long Island, and Westchester County, New York, within the Northwell Health...
#1Henrik Salje (University of Cambridge)H-Index: 32
#2Cécile Tran Kiem (Pasteur Institute)H-Index: 7
Last. Simon Cauchemez (Pasteur Institute)H-Index: 63
view all 17 authors...
France has been heavily affected by the SARS-CoV-2 epidemic and went into lockdown on the 17th March 2020. Using models applied to hospital and death data, we estimate the impact of the lockdown and current population immunity. We find 2.6% of infected individuals are hospitalized and 0.53% die, ranging from 0.001% in those 80y. Across all ages, men are more likely to be hospitalized, enter intensive care, and die than women. The lockdown reduced the reproductive number from 3.3 to 0.5 (84% redu...
#1Milena A. Gianfrancesco (UCSF: University of California, San Francisco)H-Index: 23
#2Kimme L. Hyrich (MAHSC: Manchester Academic Health Science Centre)H-Index: 65
Last. Jinoos Yazdany (UCSF: University of California, San Francisco)H-Index: 51
view all 17 authors...
Author(s): Gianfrancesco, Milena A; Hyrich, Kimme L; Gossec, Laure; Strangfeld, Anja; Carmona, Loreto; Mateus, Elsa F; Sufka, Paul; Grainger, Rebecca; Wallace, Zachary; Bhana, Suleman; Sirotich, Emily; Liew, Jean; Hausmann, Jonathan S; Costello, Wendy; Robinson, Philip; Machado, Pedro M; Yazdany, Jinoos; COVID-19 Global Rheumatology Alliance Steering Committee
#1Gavin Giovannoni (QMUL: Queen Mary University of London)H-Index: 107
#2Christopher Hawkes (QMUL: Queen Mary University of London)H-Index: 123
Last. Julian Gold (QMUL: Queen Mary University of London)H-Index: 27
view all 6 authors...
Cited By178
BACKGROUND AND OBJECTIVES: It is unclear how multiple sclerosis (MS) affects the severity of COVID-19. The aim of this study is to compare COVID-19-related outcomes collected in an Italian cohort of patients with MS with the outcomes expected in the age- and sex-matched Italian population. METHODS: Hospitalization, intensive care unit (ICU) admission, and death after COVID-19 diagnosis of 1,362 patients with MS were compared with the age- and sex-matched Italian population in a retrospective obs...
#1Alice LaroniH-Index: 24
#2Irene SchiavettiH-Index: 15
Last. Antonio UccelliH-Index: 66
view all 4 authors...
The CoronaVirus Disease 19 (COVID-19) pandemic is a threat of particular concern for people affected by chronic immune-mediated diseases, such as multiple sclerosis (MS), who are often treated with immunomodulatory and immunosuppressive drugs, which may increase the risk of infections in general. At the beginning of the COVID-19 pandemic, empirical guidelines on how to manage treatments for immune-mediated diseases, including MS, were released. Subsequently, the first clinical pictures and data ...
#1Hubert Mado (University of Silesia in Katowice)H-Index: 2
#2Monika Adamczyk-Sowa (University of Silesia in Katowice)H-Index: 14
Coronavirus disease 2019 (COVID-19) is now a major issue for all fields of medicine Due to the higher mortality rate among patients with chronic diseases, it has also caused concern in patients with multiple sclerosis (MS), who in addition are often receiving immunosuppressive drugs The aim of this article is to discuss what is currently known about the severity of COVID-19 in MS patients
#1Zoé L.E. van Kempen (VU: VU University Amsterdam)H-Index: 7
#2Joep Killestein (VU: VU University Amsterdam)H-Index: 56
Last. Hans-Peter Hartung (HHU: University of Düsseldorf)H-Index: 120
view all 3 authors...
Abstract null null Background null Outcomes of COVID-19 in PwMS (persons with Multiple Sclerosis) on immunosuppressive therapies, particularly B-cell depletors, can be unpredictable. There has been a concern for postponing or avoiding use of Rituximab (RTX) during the COVID-19 pandemic. We report the course and outcomes of COVID-19 in PwMS receiving RTX. null null null Methods null PwMS receiving RTX who contracted COVID-19 were closely monitored by tele-consultation and/or evaluated during hosp...
(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and res...
#1Steve Simpson-Yap (University of Melbourne)H-Index: 5
#2Edward De Brouwer (Menzies Research Institute)
Last. Geys L (GAU: University of Göttingen)H-Index: 3
view all 47 authors...
Background and Objectives null People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. null Methods null Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1–12 countries). Demographic (age, sex), clinical (MS phenotype, disab...
#1Schiavetti Irene (UniGe: University of Genoa)
#2Ponzano Marta (UniGe: University of Genoa)
Last. Sormani Maria Pia (UniGe: University of Genoa)
view all 6 authors...
Abstract null null Background null COVID-19 may spread through various ways ranging from asymptomatic to severe forms, until respiratory failure, critical conditions and death occurs. There is a particular concern for patients affected by multiple sclerosis, especially for those under disease-modifying treatments. Some studies have found an association between anti-CD20 therapies (especially rituximab) and severe COVID-19. However, results were not always clear and thus a systematic review was h...
#1Mahdi Barzegar (IUMS: Isfahan University of Medical Sciences)H-Index: 8
#2Omid Mirmosayyeb (IUMS: Isfahan University of Medical Sciences)H-Index: 12
Last. Nasrin Asgari (University of Southern Denmark)H-Index: 26
view all 8 authors...
Abstract null null Background null We conducted this systematic review and meta-analysis to assess the risk of coronavirus disease (COVID-19), clinical features and outcome among patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). null null null Methods null We systematically searched PubMed, Scopus, Web of Science, and Embase from December 1, 2019, to July 2, 2021. The gray literature including the references of original studies, review studies, conference abstracts, and WHO COVID-19 ...
#1Fereshteh Ghadiri (Tehran University of Medical Sciences)H-Index: 4
#2Mohammad Ali Sahraian (Tehran University of Medical Sciences)H-Index: 56
Last. Abdorreza Naser Moghadasi (Tehran University of Medical Sciences)H-Index: 14
view all 4 authors...
Abstract null null Background null At this time vaccination against SARS-CoV2 is a global priority. Cases with multiple sclerosis (MS) were among the first vaccinated populations in Iran. We evaluated the change in the frequency of COVID-19 after vaccination and the associated factors with severe COVID-19 infection before and after full vaccination. null null null Methods null A questionnaire was validated to investigate the basic characteristics (age, gender, education, body mass index, smoking...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.